ArticleBlood2018
Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation.
2 registry-linked trialsAbstract readLetter
In one paragraph
Article in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 33 papers.
0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 2, Monocentric, Pilot Study to Evaluate Safety and Efficacy of CC 486 (Oral Azacitidine) Plus Best Supportive Care as Maintenance of Response to sc Azacitidine in IPSS Higher Risk Elderly MDS Patients
NCT06923488 phase1 / phase2recruitingnot on this mapstarted 2025, after this paper: background citation
Phase I/II Study of Leflunomide in Combination With Decitabine for Treatment of Relapsed or Refractory (R/R) Myelodysplastic Syndromes (MDS)
Who cites it
33 citing papers in PubMed.
- Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II study.Journal of hematology & oncology · 2026Trial
- Checkpoint immunotherapy is associated with preferential activation of tumor antigen-specific CD4Blood neoplasia · 2025Trial
- [Efficacy and safety of generic azacitidine in Chinese patients with higher-risk myelodysplastic syndromes: a multicenter, prospective, single-arm study].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2020Trial
- Article
- Real-World Management of HMA-Related Myelosuppression During MDS Treatment in the Canadian Landscape.Current oncology (Toronto, Ont.) · 2026Review
- Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.Blood cancer journal · 2026Article
- Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement.Blood · 2025Article
- Integrating advanced analytical methods to assess epigenetic marks affecting response to hypomethylating agents in higher risk myelodysplastic syndrome.Molecular medicine (Cambridge, Mass.) · 2025Article
- Beyond Hypomethylating Agents: Novel Therapies and Targeted Approaches.Clinical hematology international · 2025Review
- Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities.Current hematologic malignancy reports · 2024Review
- Measurable (Minimal) Residual Disease in Myelodysplastic Neoplasms (MDS): Current State and Perspectives.Cancers · 2024Review
- A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents.Annals of hematology · 2024Article
- Article
- CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine.Haematologica · 2023Article
- What's Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach.Cancers · 2023Review
- How I Manage Transplant Ineligible Patients with Myelodysplastic Neoplasms.Clinical hematology international · 2023Review
- Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients withLeukemia & lymphoma · 2023Article
- Are We Ready For "Triplet" Therapy in Higher-Risk MDS?Clinical hematology international · 2023Article
- Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS).Blood cancer journal · 2022Article
- Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease.Journal of hematology & oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Amer M ZeidanDepartment of Internal Medicine, School of Medicine.ORCID 0000-0001-7017-8160
Maximilian StahlDepartment of Internal Medicine, School of Medicine.ORCID 0000-0002-1299-5901
Xin HuCancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center at Yale University School of Medicine.
Rong WangCancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center at Yale University School of Medicine.
Scott F HuntingtonDepartment of Internal Medicine, School of Medicine.ORCID 0000-0001-7071-6475
Nikolai A PodoltsevDepartment of Internal Medicine, School of Medicine.
Steven D GoreDepartment of Internal Medicine, School of Medicine.ORCID 0000-0002-3649-8758
Xiaomei MaCancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center at Yale University School of Medicine.ORCID 0000-0001-8156-8404
Amy J DavidoffCancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center at Yale University School of Medicine.ORCID 0000-0001-8141-9249
Funding
Yale Pathology Tissue Services Shared ResourceP30CA016359 · NCI · YALE UNIVERSITY · PI MEGAN C KING · 1985 to 2026
$85.0MNCI NIH HHS N01 PC035136NCI NIH HHS N01 PC035139NCI NIH HHS N02 PC015105NCI NIH HHS P30 CA016359
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsAzacitidineDecitabineDNA MethylationFemaleHumansMaleMiddle AgedMyelodysplastic SyndromesPrognosisRetrospective StudiesStem Cell TransplantationSurvival RateAzacitidineDecitabine
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT04806906ClinicalTrials.gov
NCT06923488ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.